Сульпирид

Quick links

Choose a section

Quick links to important sections

Advertisements

Сульпирид

Selected form

Advertisements
Advertisements

Method of action: Antipsychotic

Treatment option: Schizophrenia

Advertisements

Overview of Сульпирид

Quick Facts

Property Description
Active ingredient Sulpiride (INN)
Form Typically tablets or capsules for oral use
Pharmacological class Substituted Benzamide; Atypical Antipsychotic
Common use Management of Schizophrenia and/or Major Depressive Disorder
Origin Developed in France in the mid-1960s

Sulpiride is an established, prescription-only medication primarily used to manage certain serious mental health conditions. As the International Nonproprietary Name (INN) for the drug, Sulpiride is the active compound found in several brand-name products across the globe, such as Dogmatil.

Chemically, Sulpiride is classified as a substituted benzamide and functions as an antipsychotic agent. It is recognized for its selective activity, primarily as an antagonist (blocker) of dopamine D2 and D3 receptors. This means the medication works by adjusting how the brain processes dopamine, a neurotransmitter linked to mood and motivation.

The medication's dual therapeutic capacity is a differentiating feature: it is often used at higher doses for psychotic disorders like schizophrenia and at lower doses to address certain types of depression and vertigo. Sulpiride is used as a pharmacotherapeutic treatment for the acute management of schizophrenia, where it has a recognized role in helping to stabilize severe symptoms when treatment is first initiated.

Advertisements

What side effects are possible with Сульпирид?

Possible Side Effects and Safety Information

Official regulatory documents classify the adverse reactions associated with Sulpiride based on frequency and the affected body system. The most commonly documented adverse events often involve the endocrine system and the central nervous system, reflecting the medicine's mode of action as a dopamine antagonist.


Regulatory Classification of Adverse Reactions

The frequency of observed adverse effects is categorized in official labeling:

  • Common Reactions (occurring in 1 in 100 to 1 in 10 patients) include hyperprolactinaemia (increased prolactin levels), sedation, insomnia, weight gain, and extrapyramidal disorder (e.g., tremor, parkinsonism). Gastrointestinal issues like constipation and nausea are also classified as common.
  • Uncommon Reactions include leukopenia (decreased white blood cells).
  • Not Known Frequency reactions are those reported in post-marketing surveillance where incidence cannot be reliably estimated.

Serious Adverse Reactions and Safety Constraints

The official safety profile highlights risks of certain serious adverse reactions regardless of frequency. These include Neuroleptic Malignant Syndrome (NMS), a potentially life-threatening condition, as well as a risk of QTc prolongation and Torsade de pointes, which are forms of serious cardiac arrhythmia. The risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is also documented.

Regulatory safety constraints prohibit the use of Sulpiride in individuals with certain pre-existing conditions, such as prolactin-dependent tumors or pheochromocytoma.

Specific safety considerations exist for special populations: older adults are noted to have an increased risk of sedation and orthostatic hypotension (dizziness upon standing). The risk of tardive dyskinesia is associated with long-term exposure to the medication.

Advertisements

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

The official regulatory documentation defines the Sulpiride overdose profile by a range of serious clinical manifestations that require immediate medical intervention. Overdose is characterized by Central Nervous System (CNS) effects, including agitation, confusion, clouding of consciousness, and CNS depression, along with pronounced extrapyramidal symptoms such as dystonia, trismus, and increased muscle tone. Hypersalivation and vomiting may also occur. The severity of these manifestations is noted to be dose-dependent.

Mandated Emergency Action

Immediate medical attention must be sought upon any suspected overdose or the observation of severe symptoms. Documented life-threatening outcomes include coma, convulsions/seizures, and Neuroleptic Malignant Syndrome ( NMS). The most critical documented risks involve the cardiovascular system, encompassing hypotension and severe ventricular arrhythmias, specifically Torsade de pointes and QT prolongation, which can lead to cardiac arrest and sudden death.

Supportive Management and Monitoring Requirements

Regulatory guidance mandates continuous cardiac ( ECG) monitoring and hospital observation due to the potential for severe, delayed cardiac complications. No specific antidote is known. Treatment is limited to symptomatic and supportive measures. Procedures such as gastric lavage or activated charcoal may be considered, and antiparkinsonian medication may be used to address extrapyramidal symptoms, as described in official documentation.

Advertisements

Therapeutic Uses of Сульпирид

This medication is considered relevant for the acute management of schizophrenia, which is a common therapeutic area. The medicine is commonly used to help with conditions that present with acute or unstable symptom patterns, including Schizophrenia, Major Depressive Disorder, and specific functional body complaints such as vertigo and dyspepsia. It is applied in addressing both the positive symptoms of psychosis and the apathy related to mood disorders. This therapeutic approach provides support that helps ease the overall symptom load and helps maintain a sense of stability during periods of heightened distress.


Quick Fact: Focus on Symptomatic Relief

Property Description
Symptom Focus Symptoms such as severe thought disturbances, apathy, low drive, and functional nausea/vertigo
Clinical Scenarios Applied in clinical settings that involve acute or unstable symptom patterns, long-term maintenance, and managing functional body complaints

Regulatory References

  1. National Institutes of Health (NIH) systematic review
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Status for Sulpiride

The eligibility for using Sulpiride is strictly defined by regulatory authorities based on pre-existing conditions and demographic factors. Use is generally established for Adults (18+ years) who do not have documented contraindications.

Populations Who Must Not Use Sulpiride (Contraindicated)

The medicine is strictly prohibited for individuals with:

  • Hypersensitivity to sulpiride.
  • Prolactin-dependent tumors (e.g., prolactinoma or breast cancer).
  • Phaeochromocytoma or Acute Porphyria.
  • Concomitant treatment with Levodopa or specific dopamine agonists.

Age and Physiological Restrictions

  • Pediatric Population: Use is not recommended in children under 14 years of age due to insufficient clinical experience.
  • Older Adults (Geriatric): Use requires particular caution and close monitoring due to increased susceptibility to certain risks.
  • Pregnancy: Use is generally not recommended and is only considered if the potential benefit is judged to outweigh the known risks.
  • Lactation: Breastfeeding is not recommended because the medicine is excreted into breast milk.

Conditional Use

Patients with renal impairment are eligible but require a restricted or reduced dose. Use also requires caution and monitoring in individuals with a history of epilepsy, Parkinson's disease, cardiovascular risk factors (e.g., for QTc prolongation), and risk factors for stroke.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sulpiride’s interaction profile is documented in regulatory labeling and involves pharmacodynamic and absorption-related interaction patterns. All statements reflect official constraints defined by health authorities.


Prohibited Combinations and Restrictions

Co-administration with Dopaminergic Anti-Parkinson Medicines is a formally documented contraindicated combination. These agents, including Levodopa, Ropinirole, and Amantadine, are prohibited due to the risk of reciprocal antagonism of effects.

Co-consumption of alcoholic beverages and medicines containing alcohol must be avoided because alcohol may potentiate the sedative effects of Sulpiride, as stated in regulatory documents.


Pharmacodynamic and Absorption Interactions

  • Additive CNS Effects: Co-administration with other CNS Depressants (e.g., narcotics, benzodiazepines) may result in an additive CNS depressant effect, leading to increased sedation.
  • Additive Cardiotoxicity Risk: Use with medicines known to prolong the QT interval or induce Torsade de Pointes is not recommended. This includes Bradycardia-inducing medicines and drugs that cause electrolyte imbalance (e.g., stimulant laxatives).
  • Absorption Reduction (Timing Rule): The absorption of Sulpiride is decreased when taken with Antacids (containing Aluminium or Magnesium salts) or Sucralfate. To mitigate this reduction in exposure, Sulpiride must be administered at least two hours before these agents.
Advertisements

Mechanism of Action

Selective D2/ D3 Dopamine Receptor Antagonism

Сульпирид primarily functions as a selective blocker (antagonist) of the Dopamine D2 and D3 receptors within the central nervous system, particularly in regulatory pathways such as the mesolimbic system. By binding to these receptors, the drug modifies early molecular steps that shape systemic physiological outcomes, altering the signaling dynamics of dopaminergic circuits.


Dose-Dependent Pathway Modulation

The drug engages mechanisms that influence feedback regulation within pathways by exerting a concentration-dependent effect. At lower concentrations, Сульпирид can selectively block presynaptic D2 autoreceptors, which removes an inhibitory signal and leads to an increase in dopamine release. At higher concentrations, it blocks postsynaptic D2 receptors, which suppresses signaling and results in altered transmission dynamics within targeted pathways.


Neuroendocrine System Influence

Antagonism of the D2 receptors in the tuberoinfundibular pathway affects systems where specific transmitters dominate the humoral axis. By inhibiting the natural dopamine-mediated control on the pituitary gland, this mechanism leads to the physiological adjustment of increased prolactin release (hyperprolactinemia), which occurs as a direct result of the D2 receptor mechanism in this pathway.

Advertisements

Dosage and Administration Information

Administration Guidelines

Sulpiride is primarily intended for oral administration through tablets, capsules, or an oral solution, although an intramuscular injection form is also documented for managing acute phases of treatment. The total prescribed daily dosage is typically administered in two divided doses, taken in the morning and early evening.

The standard daily dosage is specific and depends on the prescribed therapeutic need. The usual starting range is 400 mg to 800 mg per day. The dose can vary significantly, with a maximum recommended amount reaching 2400 mg per day (1200 mg twice daily) for certain high-dose regimens. For patients requiring a more alerting effect, the daily dosage may be reduced toward 400 mg.

For proper administration, tablets should be swallowed whole with water. In cases where a dose is missed, guidance indicates that the missed dose should be skipped if it is almost time for the next scheduled dose, thereby preventing the intake of a double amount.

Population-Specific Use and Course Duration

Dosage adjustments are required for patients with kidney function impairment. Since the drug is largely eliminated by the renal route, the dose must be reduced or the interval between doses increased based on the degree of impairment. The same dose ranges are applicable to older adults, but a dose reduction is required if renal dysfunction is present. Clinical experience is insufficient to permit specific recommendations for children under 14 years of age.

Treatment is often administered long-term, and the protocol requires that the dosage must be slowly decreased before total withdrawal to prevent recurrence of symptoms.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sulpiride


Evidence for Use in Schizophrenia

Research examining the use of Sulpiride for schizophrenia includes various types of studies, such as randomized controlled trials (RCTs) and comprehensive meta-analyses that combine findings from multiple sources. These studies were primarily used in research exploring how symptoms change over time in adult patients with either acute or long-term schizophrenia. Researchers monitored changes in core psychiatric symptoms using standardized rating scales, and also tracked outcomes reflecting daily functioning or activity level and treatment persistence (how long patients continued taking the medication).

Studies focusing on episodes where symptoms become more noticeable have reported that in comparative trials, the drug’s observed short-term changes in symptom severity have been described in relation to other established treatments. What remains uncertain is the full picture of long-term effects, particularly concerning outcomes such as social integration and the need for hospital care, which are not fully established by existing controlled trials.


Evidence for Use in Major Depressive Disorder

Sulpiride was studied for its use in managing depressive states, often at lower doses than those used for psychosis. The evidence comes primarily from systematic reviews that have aggregated data from older, controlled clinical studies. Research examined the drug both as a standalone option and as an augmentation strategy (or strategy to complement another treatment) for depressive states. Evidence describes that different patterns were observed when the drug was evaluated in older adults with milder degrees of depression.

A key limitation in this area is that the evidence relies on older controlled trials; as a result, evidence quality varies across studies. Additionally, the data for long-term outcomes and its specific value when used to augment other treatments are still emerging and not as well defined as its use as a single treatment.


What Is Still Uncertain About Sulpiride Research

The overall research landscape has several known limitations noted by scientific reviewers. The most significant gap is the scarcity of high-quality randomized controlled trials (RCTs) that directly compare Sulpiride to an inactive placebo pill across all indications; comparative evidence is lacking in many areas where studies against an inactive treatment remain limited.

Research also suggests that the evidence quality varies across studies, particularly for the less common indications like functional body complaints. The sample sizes were modest in some of the older studies, leading to uncertainty in specific findings. Overall, these limitations mean that while the drug has been studied for multiple conditions, the certainty remains low for some of the detailed, functional outcomes.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Сульпирид (FAQ)

Q: How long does it typically take to start noticing effects from Сульпирид?

Research has described that early changes, such as mood elevation, have been observed after a few days of treatment, with effects on core symptoms examined later in the process. However, the full therapeutic benefit of the medicine may take longer, and it is established as a drug intended for regular administration.

Q: Is Сульпирид a short-term or long-term medication?

Treatment is often described in regulatory documents as being administered long-term, particularly for chronic conditions. Regulatory protocol suggests that use is often long-term, and continued administration is part of the strategy to manage the recurrence of symptoms. The duration of use is ultimately determined by the prescribing professional.

Q: What happens if I forget to take a dose of Сульпирид?

Official patient guidance states that if a dose is missed, it should be skipped if it is almost time for the next scheduled dose. This is to ensure a double amount is not taken. Specific circumstances regarding a missed dose should be clarified with the prescribing professional.

Q: Can men experience side effects related to hormones while taking Сульпирид?

Yes, common reactions listed in official documents include hyperprolactinaemia, which is an increase in prolactin levels. Uncommon side effects such as breast enlargement and erectile dysfunction have also been documented. Gynecomastia (breast tissue growth) is a reaction that has also been reported.

Q: Can Сульпирид cause changes in menstrual cycles?

According to official regulatory documents, both menstrual disorders and amenorrhea (absence of menstrual periods) are listed as common reactions. These effects are associated with the drug's mechanism of action which can lead to hormonal changes, such as increased prolactin.

Q: Is it safe to drive or operate machinery while taking Сульпирид?

Due to the possibility of sedation and drowsiness, which are common side effects, regulatory safety constraints advise caution regarding activities that require alertness, such as driving or operating machinery.

Q: Is it okay to take antacids (stomach medicines) at the same time as Сульпирид?

Simultaneous use with antacids containing Aluminium or Magnesium salts, or Sucralfate, is not advised. Official guidance states the absorption of Sulpiride is decreased when taken together. Therefore, a time gap of at least two hours is required before administering these agents.

Q: Is the mechanism of action of Сульпирид fully understood?

The drug is described in official documents as a selective blocker of the dopamine D2 and D3 receptors. While its primary mechanism is defined, research suggests that its full properties show distinctions from other similar drugs, indicating a complex and concentration-dependent action that continues to be examined.

Q: Is Сульпирид known to cause sexual side effects?

Yes, uncommon side effects listed in regulatory documents include abnormal orgasm and erectile dysfunction. Additionally, the common side effect of hyperprolactinaemia (increased prolactin) is often associated with potential changes in sexual function.

Q: Does the time of day I take Сульпирид matter?

Yes. The total daily dosage is required to be split into two doses, typically taken in the morning and early evening. This schedule is designed as the division of the dose is noted to influence the drug’s effects, including the potential for an alerting effect.

Q: Can Сульпирид pass into breast milk?

Yes, official eligibility constraints confirm that the medicine is excreted into breast milk. For this reason, official safety constraints list breastfeeding as a circumstance where the drug’s use is not advised.

Q: Does a person need to have liver function checked while taking Сульпирид?

Official regulatory documents list 'increased hepatic enzyme' (an indicator of liver function) as a common adverse reaction. The potential for this reaction suggests that monitoring may be included as part of an individual’s treatment protocol.

Q: What is the half-life of Сульпирид (how long it stays in the body)?

According to official pharmacokinetic data documented in the product information, the plasma half-life of the drug in humans is approximately eight hours. This figure describes the time it takes for half of the dose to be eliminated from the bloodstream.

Q: Does Сульпирид affect blood pressure?

The official documentation lists orthostatic hypotension as an uncommon adverse reaction. This condition is a sudden drop in blood pressure that can cause dizziness upon standing.

Q: Is it necessary to have blood tests done regularly while taking Сульпирид?

Official documentation notes the potential for certain adverse reactions, such as low white blood cell counts (leukopenia) and electrolyte imbalances, which are often monitored via blood tests. The requirement for such monitoring is part of the established treatment protocol.

Q: Are there dietary restrictions required when using Сульпирид?

Official documentation states that alcohol must be avoided due to the potential for it to increase the medicine’s sedative effects. Aside from alcohol, the medicine may generally be taken with or without food.

Q: Is Сульпирид commonly used in other countries besides [Country X]?

Yes. While this medicine is not approved in all regions globally, it is an established medication with official regulatory documentation from agencies in many other countries, including those in Europe, Canada, and Australia.

Q: Is it true that Сульпирид is sometimes used at low doses for different effects?

Yes. The official product information states that the drug's activity is dose-dependent. It is used at higher doses for certain severe symptoms, and has been studied for conditions such as depression and vertigo. The documentation notes that a lower dose is described as potentially increasing the alerting effect.

Q: Is it okay to stop taking Сульпирид suddenly?

Official protocol describes that the dosage must be slowly decreased before total cessation. This strategy is established to help manage the potential for symptoms to return. The strategy and decision regarding cessation is part of the personalized medical guidance provided by a healthcare professional.

Q: Does Сульпирид affect a person's ability to concentrate?

Because common side effects include sedation and drowsiness, official documents indicate that a person’s attention and ability to concentrate may be affected while using this medication.

Advertisements

How should Сульпирид be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Sulpiride are strictly defined by regulatory labeling to maintain the product's integrity and safety.

Requirement Official Regulatory Statement
Temperature Limit Do not store the medicine above 25 C
Protection Keep the product in its original container and protected from light, moisture, and heat
Stability (Opened) The oral solution must be discarded 3 months after the container is opened
Child Safety A mandated requirement is to keep out of the reach of children
Disposal Unused or expired medication must be disposed of in accordance with local government requirements

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Сульпирид found in:

A-Z Index: